AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (613.3 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Letter | Open Access

Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation

Kaibo Dinga,b, Zhongsheng Penga,b, Yanjun Xua( )
Department of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China
Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, China

Peer review under the responsibility of the Genes & Diseases Editorial Office, in alliance with the Association of Chinese Americans in Cancer Research (ACACR, Baltimore, MD, USA).

Show Author Information

References

1

Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81–94.
Crossref Google Scholar
2

Lu C, Wei XW, Wang Z, et al. Allelic context of EGFR C797X-mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes. J Thorac Oncol. 2024;19(4):601–612.
Google Scholar
3

Shi Y, Zhang S, Hu X, et al. Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation. J Thorac Oncol. 2020;15(6):1015–1026.
Google Scholar
4

Starrett JH, Guernet AA, Cuomo ME, et al. Drug sensitivity and allele specificity of first-line osimertinib resistance EGFR mutations. Cancer Res. 2020;80(10):2017–2030.
Crossref Google Scholar
5

Li M, Qin J, Xie F, Gong L, Han N, Lu H. L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment. Discov Oncol. 2022;13(1):72.
Crossref Google Scholar
Genes & Diseases
Volume 12 Issue 2,
March 2025
Article number: 101408
DOI: 10.1016/j.gendis.2024.101408
Cite this article:
Ding K, Peng Z, Xu Y. Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation. Genes & Diseases, 2025, 12(2): 101408. https://doi.org/10.1016/j.gendis.2024.101408

112

Views

7

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Altmetrics
Received: 22 February 2024
Published: 07 September 2024
© 2024 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Return